The effect of quercetin supplementation on nonalcoholic fatty liver disease

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 110

Inclusion Criteria

Inclusion criteria include: a willingness to participation; age 18-65 years; non-alcoholic fatty liver diagnosed by ultrasonography and liver function test Tests( Alanine transaminase and Aspartate transaminase (more than 30u/l in men and more than 20u/l in women)) ; Lack of alcohol abuse (taking more than 10 grams per day for women and more than 30 grams per day for men); Body mass index equal to or greater than 40Kg/M2; Lack of other acute and chronic liver disorders (hepatitis B and C, etc.); Wilson's disease; cirrhosis; no history of biliary tract disease; acute heart failure disease; renal; pulmonary; infectious diseases; diabetes; cancer; inherited disorders affecting liver condition (iron storage disease, etc.); the absence of pregnancy and lactation; disease related to thyroid disorders; No history of weight loss surgery in the past year; the absence of lose weight in the past three months and In general, lack of increase or decrease in weight regimes during the three months prior to sampling; Autoimmune diseases such as primary biliary cirrhosis, autoimmune hepatitis, sclerosing cholangitis; Non-use of antioxidant supplements during one month prior to sampling; Lack of use of effective drugs against weight during the three months prior to sampling; Do not use multivitamin-minerals and drugs that are most likely associated with this disease(Antiepileptic drugs, amiodarone, corticosteroids, phenytoin, lithium, roacutan, tamoxifen, methotrexate, aspirin, 5-fluorouracil, zidovudine, a synthetic estrogen, inhibitors of hydroxymethyl glutaryl coa reductase and etc);Lack of exposure to pesticides and insecticides such as: carbon tetrachloride; trichloroethylene; Avoiding the use of drugs that are likely to overlap with quercetin; including anticoagulants, inhibitors of CYP3A4 and ....
Exclusion criteria included: Not wanting to continue working; diseases that require special treatment; Reduction of more than 10% of baseline body weight during the intervention period; not consumption of more than 10% of the supplements in any follow-up period and in general, any inconsistent with the inclusion criteria

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ipid profile. Timepoint: at first and the end of study. Method of measurement: enzymathic method.;Liver enzymes. Timepoint: at first and the end of study. Method of measurement: enzymathic method.;Inflammatory markers. Timepoint: at first and the end of study. Method of measurement: ELISA method.

Secondary Outcome Measures

Name	Time	Method
Body composition. Timepoint: at firt of the study and the end of forth,eighth and Twelfth weeks. Method of measurement: BIA.;Weight. Timepoint: at firt of the study and the end of forth,eighth and Twelfth weeks. Method of measurement: With light clothing and using Seca scales with 100 gAccuracy.;Height. Timepoint: Accuracy. Method of measurement: ???? ??? ?? ??????? ?? ?? ??? ??? ?? ??? 0.1 ????? ???.;Waist circumference. Timepoint: at firt of the study and the end of forth,eighth and Twelfth weeks. Method of measurement: Using a tape measure between the lowest gear and iliac crest with accuracy of 0.5 cm.;Hip circumference. Timepoint: at firt of the study and the end of forth,eighth and Twelfth weeks. Method of measurement: Using a tape measure at the bigest part of the hips.